Kim Sungwon, Kim Sunwoo, Do Jong Geol, Hwang Ji Hye
Department of Physical and Rehabilitation Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Department of Occupational Therapy, Graduate School of Medical Science, Konyang University, Daejeon 35365, Republic of Korea.
Diagnostics (Basel). 2024 Jul 9;14(14):1464. doi: 10.3390/diagnostics14141464.
To investigate the effects of intra-articular glenohumeral joint triamcinolone injection in treating secondary adhesive capsulitis after breast cancer surgery.
This study prospectively enrolled 37 participants, including 22 in the breast cancer surgery group and 15 in the idiopathic group. All participants received intra-articular glenohumeral joint triamcinolone injection in the affected shoulder joint. The clinical outcomes included the Shoulder Pain and Disability Index (SPADI), passive range of motion (PROM), and pain intensity on the Numeric Rating Scale (NRS), which were evaluated before the intervention and 1, 3, and 6 months after. The primary outcome of this study was the mean difference in the total SPADI from baseline to 6 months after the intervention.
The mean differences in the total SPADI scores from baseline to 6 months after the intervention were 36.2 ± 16.4 and 47.9 ± 15.2 in the breast cancer surgery group and the idiopathic group, respectively. There was no significant difference between the two groups ( = 0.1495). However, the improvements in the SPADI pain subscale at the 3- and 6-month follow-up visits (-31.2 vs. -48.8, = 0.042; -34.1 vs. -50.7, = 0.0006) and the PROM of abduction at the 3-month follow-up (52.4 vs. 70.3, = 0.0072) were inferior in the breast cancer surgery group compared to the idiopathic group. There were no adverse events in either group.
Intra-articular triamcinolone injection is an effective and safe treatment option for adhesive capsulitis after breast cancer surgery; however, it has less effect than for idiopathic adhesive capsulitis.
探讨关节内注射曲安奈德治疗乳腺癌术后继发性粘连性关节囊炎的效果。
本研究前瞻性纳入37名参与者，其中乳腺癌手术组22名，特发性组15名。所有参与者均在患侧肩关节进行关节内注射曲安奈德。临床结局包括肩关节疼痛和功能障碍指数（SPADI）、被动活动范围（PROM）以及数字评分量表（NRS）上的疼痛强度，在干预前以及干预后1、3和6个月进行评估。本研究的主要结局是干预后6个月与基线相比SPADI总分的平均差异。
乳腺癌手术组和特发性组干预后6个月与基线相比SPADI总分的平均差异分别为36.2±16.4和47.9±15.2。两组之间无显著差异（P = 0.1495）。然而，在3个月和6个月随访时，乳腺癌手术组SPADI疼痛子量表的改善情况（-31.2对-48.8，P = 0.042；-34.1对-50.7，P = 0.0006）以及3个月随访时外展的PROM（52.4对70.3，P = 0.0072）均低于特发性组。两组均未发生不良事件。
关节内注射曲安奈德是治疗乳腺癌术后粘连性关节囊炎的一种有效且安全的治疗选择；然而，其效果比特发性粘连性关节囊炎差。
